


## R079

Cat. No.:	HY-163027
CAS No.:	2115659-62-4
Molecular Formula:	C <sub>11</sub> H <sub>11</sub> N <sub>3</sub> O <sub>3</sub> S
Molecular Weight:	265.29
Target:	Keap1-Nrf2
Pathway:	NF-κB
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	R079 (compound 17) is a selective, orally active Nrf2 activator. R079 increases Nrf2 translocation activity (EC <sub>50</sub> = 32.41 μM). R079 can neutralize excess levels of reactive oxygen species through activating Nrf2. R079 has anti-inflammatory properties and can be used in multiple sclerosis research <sup>[1]</sup> .														
<b>In Vitro</b>	R079 (2-10 μM) increases expression of Nrf2 and HO-1 in THP-1 cells <sup>[1]</sup> . R079 shows microsomal stability, with t <sub>1/2s</sub> of >60 min in mouse, rat, dog, monkey and human microsomes <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.														
<b>In Vivo</b>	R079 (30-90 mg/kg, p.o., b.i.d for 28 days) demonstrates a robust dose-dependent reduction in disease severity in mouse EAE model <sup>[1]</sup> .  PK Parameters for R079 in Balb/c Mice <sup>[1]</sup> <table border="1" data-bbox="347 1268 1515 1806"> <thead> <tr> <th>Parameter</th> <th>Balb/c Mice (p.o., 5mg/kg)</th> </tr> </thead> <tbody> <tr> <td>clearance (mL/min/kg)</td> <td>2.01</td> </tr> <tr> <td>half-life (h)</td> <td>1.0</td> </tr> <tr> <td>V<sub>ss</sub> (L/kg)</td> <td>0.14</td> </tr> <tr> <td>oral AUC (ng·h/mL)</td> <td>22900</td> </tr> <tr> <td>oral C<sub>max</sub> (ng/mL)</td> <td>19600 (73.96 μM)</td> </tr> <tr> <td>bioavailability (%F)</td> <td>56</td> </tr> </tbody> </table> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	Parameter	Balb/c Mice (p.o., 5mg/kg)	clearance (mL/min/kg)	2.01	half-life (h)	1.0	V <sub>ss</sub> (L/kg)	0.14	oral AUC (ng·h/mL)	22900	oral C <sub>max</sub> (ng/mL)	19600 (73.96 μM)	bioavailability (%F)	56
Parameter	Balb/c Mice (p.o., 5mg/kg)														
clearance (mL/min/kg)	2.01														
half-life (h)	1.0														
V <sub>ss</sub> (L/kg)	0.14														
oral AUC (ng·h/mL)	22900														
oral C <sub>max</sub> (ng/mL)	19600 (73.96 μM)														
bioavailability (%F)	56														
<b>Animal Model:</b>	mouse experimental autoimmune encephalomyelitis (EAE) model <sup>[1]</sup>														

---

Dosage:	30, 60, and 90 mg/kg
Administration:	Oral gavage (p.o.), b.i.d for 28 days
Result:	Demonstrated a robust dose-dependent reduction in disease severity (41% reduction in clinical score at 30 mg/kg to 89% at 60 mg/kg), p.o. (60, 90 mg/kg) increased levels of Nrf2 for an 8 h period in mouse thymus.

---

## REFERENCES

[1]. Simon J. Shaw, et al. Tuning the Reactivity of Nuclear Factor Erythroid 2 Related Factor 2 (Nrf2) Activators for Optimal in Vivo Efficacy. ACS Medicinal Chemistry Letters. 2023 Article ASAP.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA